Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153513 | 0.77 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL14457463 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL21584140 | 0.74 | NPC1 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5215551 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL8377128 | 0.73 | CA1 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL27262981 | 0.73 | SMN1; SMN2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL8814582 | 0.73 | SMN1; SMN2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL8814579 | 0.73 | SMN1; SMN2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL23220986 | 0.72 | CA14 (0.33) | SMN1; SMN2 | |
| SCHEMBL28393656 | 0.72 | SMN1; SMN2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | CHRNB2 4856/4885CHRNA4 4839/4885CHRNB4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.